The original data from the placebo-arms and the tricyclic-arms of all paral
lel randomized controlled three-arm studies, which had been conducted in th
e period 1979-1991 fur a drug under development in order to obtain marketin
g authorization for the indication major depression, were included in a met
a-analysis, Thirty-two placebo-controlled studies including 4314 patients w
ere analyzed. The intention to treat analysis resulted in 46% responders (a
t least 50% improvement on the Hamilton Depression Rating Scale) in the tri
cyclic antidepressant group and 31% in the placebo-group (CI95%-difference
11.5-17.1%). The number needed to treat for responders was 7 (CI95% 5-8). I
n 10 out of 33 studies, a statistically significant difference in favor of
tricyclic antidepressant compared to placebo was found for responders. The
responder rate in the placebo-group varied fi-om 6 to 52%. We conclude that
tricyclic antidepressants are efficacious in the short-term treatment of m
ajor depression. However, the magnitude of the effect is rather modest. Bec
ause 69% of the placebo-controlled studies with a tricyclic antidepressant
did not show a statistically significant difference in favor of tricyclic a
ntidepressant and the placebo rare varied considerably from study to study,
equivalence studies with tricyclic antidepressant as comparator without a
placebo-control are not sufficient fur demonstrating efficacy. Therefore in
major depression, placebo-controlled studies are still necessary to demons
trate efficacy. (C) 2001 Elsevier Science B.V. All rights reserved.